Biotechnology in Taiwan

Rakuten Medical

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox® platform, which has been shown to induce rapid and selective cell killing and tumor necrosis. Rakuten Medical is committed to its mission to conquer cancer by delivering its innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit

51 to 200 staff

Anbogen Therapeutics

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs. Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development.

11 to 50 staff

Atgenomix

Atgenomix is a data and machine learning (ML) company that provides an open standard and unified platform for operationalizing biomedical data, analytics, and ML to deliver on the promise of precision medicine. The Atgenomix cloud-based biomedical informatics platform empowers clinical laboratories to design, develop, and operate GA4GH (Global Alliance for Genomics & Health) standard orchestrated multimodal workflows of data integration, tool engineering, analysis automation, workload acceleration, and regulatory compliance management. At Atgenomix, we envision a technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide industry accessible computational lab technologies that researchers need to scale data and machine learning in the future. Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, and a Google Health trusted partner in genomics research.

11 to 50 staff

Eurofins Discovery

Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, lasting improvements in human health. Join our dynamic team! View open positions:

501 to 1000 staff

A2 Healthcare Taiwan Corporation

As a member of ITOCHU Group, A2 Healthcare Corporation contributes to the research and development of medical and pharmaceutical products through sophisticated offering of clinical research full services with footprints in the US and Asia. In particular, A2 Healthcare specializes in early phase clinical trials, serving hundreds of clients in Taiwan (86%) and worldwide (14%).

51 to 200 staff

Genomics Biosci & Tech Co Ltd

Genomics BioSci & Tech. Co, Ltd. is dedicated to advancing our understanding of genomes, with a focus on their structure, function, evolution, mapping, and editing. We specialize in cutting-edge sequencing technology, bioinformatics, and synthetic biology, enabling us to precisely assemble and analyze gene function and structure. Our services and products empower scientists to tackle real-world challenges, including increasing crop yields through genetically modified plants, developing new drugs, detecting diseases, and providing precision medicine strategies. As Taiwan's premier commercial sequencing company, with over 20 years of expertise in genomic science, Genomics BioSci & Tech. Co, Ltd. has a robust foundation in sequencing services, oligo, and peptide synthesis. We collaborate with leading academic institutions and biotech partners to develop accurate medical genetic testing, offer personalized medical information, and contribute to government research projects aimed at advancing agriculture." Pioneering a new frontier in biotech through sequencing, innovating genetics with cutting-edge cloud solutions." — Dr. Teh-Yuan Chow

51 to 200 staff

Hi-Q Marine Biotech International Ltd

Hi-Q Marine Biotech is founded in 1998, a leading marine biotechnology company in Taiwan. Hi-Q specializes in the research and development of Low Molecular Weight Fucoidan (Oligo Fucoidan), a type of clinically-proven ingredient extracted from natural brown seaweed, developed specifically for nutritional, cosmetic and animal health applications. With the passion of ‘empowering people to lead healthier lives’, Hi-Q are investing in development of cancer nutrition to fulfill the ongoing need to proper and adjunct nutrition to cancer patients as they suffer from cachexia. In addition to the own expert teams, Hi-Q collaborates with leading research institutions for advanced research and solution.#Hi-Q #FucoHiQ #Taiwan #cancer #oncology #nutrition #dietarysupplement #functionalingredients #skincare #cosmeticingredient #kelp #brownseaweed #algae #marine

51 to 200 staff

Energenesis Biomedical

Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases. Pipeline: ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase recruiting in the US and Taiwan) ENERGI-F701: hair tonic for Alopecia (Phase II, completed) ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD & RPD) ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)

11 to 50 staff

Fidelity Regulation Therapeutics

Fidelity Regulation Therapeutics Inc, FRT, is a drug development company. Based on the biomedical and basic scientific background, FRT is committed to develop drugs to fulfill unmet medical needs.

1 to 10 staff

Libo Pharma Corp

About Libo Pharma Founded in 2017, Libo Pharma Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. Our lead asset, NM-IL-12, is a first-in-class cytokine-based immunomodulator with multiple mechanisms of action, including immune regulation, hematopoiesis enhancement, radiation damage mitigation, and anti-tumor activity. Our Lead Product: NM-IL-12 NM-IL-12 has received orphan drug designation from both the U.S. FDA and European Medicines Agency (EMA) for the treatment of cutaneous T-cell lymphoma (CTCL) and is advancing into a Phase 3 clinical trial, with strong potential for regulatory approval and commercialization. The product has also completed Phase 2 clinical trials for Hematopoietic Syndrome of Acute Radiation Syndrome(HSARS) and open wound healing, and is currently expanded into new indications including diffuse large B-cell lymphoma (DLBCL) and other solid tumors—highlighting a robust and diversified pipeline. Innovation & Capabilities Libo Pharma maintains a globally competitive intellectual property portfolio, covering key markets such as the United States, Europe, and Japan. We retain full control over the manufacturing processes and biological materials related to NM-IL-12, ensuring a high level of autonomy across product development and production. Backed by a highly experienced scientific and regulatory team, we are well-positioned to drive forward our development programs from clinical validation to commercial launch. Clinical Experience To date, NM-IL-12 has been administered in over 200 human subjects, consistently demonstrating a favorable safety and efficacy profile. Its ability to be used in combination with standard therapies including chemotherapy, radiotherapy, and immune checkpoint inhibitors offers promising opportunities to enhance treatment outcomes across multiple cancer types.

11 to 50 staff

Lifeos Genomics

LifeOS Genomics was founded in 2015 on the vision of enabling accessible testing for genetic diseases. To realize this vision, we built the QLoci™ system, a fully automated “sample-to-result” molecular screening platform that offers proprietary multiplex digital PCR (mdPCR™) technology. The breakthrough of our mdPCR™ platform is the marriage of up to 100-plex assay capability in a digital PCR-on-chip format and 0.01% sensitivity, all delivered in a single microfluidic cartridge. This unique ability to provide high multiplicity assays and absolute quantitation with remarkable consistency is a game changer in fulfilling unmet medical needs, particularly in early detection and dynamic therapeutic solutions.

11 to 50 staff

Pacific Deep Ocean Biotech Ltd

Pacific Deep Ocean Biotech Co, Ltd.(PDOB) was formed to pioneer the potential applications of the rich pure source of minerals and trace elements in Deep Ocean Water. We source deep ocean water from a depth of over 600 meters near Taitung and Hualien on the east coast of Taiwan. This is a beautiful region with rugged steep mountains running down to the coast line. Over the last 15 years, the Taiwanese Government has generously sponsored research and development to improve the technologies to access deep ocean water and to concentrate the minerals and trace elements. Additionally, they have sponsored clinical, agricultural, and fisheries trials to establish the merits of deep ocean water. PDOB's mission is to commercialize the many beneficial applications using the deep ocean water. We will continue to undertake research and focus on the potential and exciting biotech applications. We aim to also expand and create employment opportunities that relate to the ocean and the history of the region. The manufacturing facilities already incorporate green technologies and environmental policies to compliment the beautiful landscape. We are seeking to establish partnerships with other innovative companies best in the industry to collaborate and utilizing our unique technologies and experience.

11 to 50 staff

Aeon Biotherapeutics Corp

We believe the only way to the highest quality of life is to have a healthy body and mind. Knowing that all of our patients have unlimited regenerative potentials, we integrate technologies into medicine to develop safer and more efficient therapies to facilitate natural healing processes and strengthen bodily functions. Biological changes will keep on influencing our daily lives; thus, we have begun a never ending quest to explore new solutions. We are Aeon Biotherapeutics and we are dedicated to creating healthier possibilities.

11 to 50 staff

Ever Supreme Bio Technology Co., Ltd. 6712.Two

Ever Supreme Bio Technology is a clinical-stage biotech company focused on developing next-generation allogeneic cell therapies for solid tumors. Its lead candidate, CAR001, combines gamma delta T cells targeting HLA-G with BiTE-mediated PD-L1 engagement to overcome two major barriers in current solid tumor treatment: tumor heterogeneity and immune evasion. With operations in Taiwan and early clinical trials underway, Ever Supreme also runs a revenue-generating CDMO platform and is expanding its pipeline to include stem cell and exosome-based therapies. Backed by a strong IP portfolio across seven countries and deep clinical expertise, the company is strategically positioned to deliver scalable, off-the-shelf immunotherapies that are safe, effective, and globally accessible.

51 to 200 staff

Strong Biotech Corporation

Combined with professionals in clinical gastroenterology, Strong developed Helicobacter pylori in vitro diagnostic devices and related biotech materials. Strong is Taiwan and the world’s first company specializing in producing both paper and gel type Helicobacter pylori in vitro diagnostic test, providing rapid diagnosis of peptic ulcer caused by the H. pylori as the basis of doctor’s prescription.

11 to 50 staff

Apex Biotechnology Corp 1733

1 to 10 staff

Medigen Biotechnology Corp 3176

Medigen Biotechnology Corp (3176) is a biotechnology company based out of Yuanqu Street, Nangang District, Taipei, Taiwan.

11 to 50 staff

Retain Biotech

Retain Biotech is the first joint venture of National Taiwan University and YongLin Healthcare Foundation, incorporating tripartite resources from industry, academia and research sectors. We integrate the research strength from National Taiwan University, years of extensive clinical experience in the field of stem cell therapy from Tai Chen Cell Therapy Center and vast resources put into the fields of preventive medicine and cancer therapy by YongLin Healthcare Foundation. From the perspective of preventive medicine, Retain Biotech achieves personalized healthcare management with the preservation of stem cells or immune cells at the early stage and high-end healthcare management. By integrating big data analysis, the most appropriate disease management will be provided by our service. When disease occur, we can maximize and optimize the application of medical resources.

11 to 50 staff

Immunwork

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

11 to 50 staff

Atp-Bio Co., Ltd

Health and Beauty We Create for the World Private label and contract manufacturing of health and beauty food, drink, and cosmetics. We efficiently supply good-quality products and services.

51 to 200 staff

Development Center For Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. The division of Industrial Promotion provides industrial information, services, facilitates technology transfer, and overall foster international partnerships for commercialization. Many of these functions are performed in conjunction with outpost team members managing other government-sponsored programs, such as the Biotechnology and Pharmaceutical Industries Program Office (BPIPO; commissioned by the Industrial Development Bureau, MOEA), and the Nankang Biotech Incubation Center (NBIC; commissioned by the Small and Medium Enterprise Administration, MOEA). DCB is dedicated to R&D in botanic drug products, pharmaceuticals, biologics, animal pharmacology, and innovative and explorative research. DCB also establishes itself as a licensing technology platform. At present, the therapeutic areas for drug development include cancer, diabetes, as well as infectious, inflammatory and cardiovascular diseases.

201 to 500 staff

Aidmics Biotechnology

Aidmics Biotechnology dedicates itself to providing solutions in microscopic scales. Ever since the launch of its very first product, the iSperm Analyzer, Aidmics has received attentions from across the world, including Reuters, Fast Company, among others.

11 to 50 staff

Tools

To accomplish your research work more efficient, we provide "TOOLS" to fulfill all of your creativity needs."TOOLS" specializes in bringing scientists "total solution" products for all applications of biomedical research from DNA to proteins including molecular biology reagents (immunology, PCR, qPCR and nucleic acid purification kits etc.), customized products and services (miRNA mimics and inhibitors, siRNA synthesis and peptide synthesis). Our enthusiastic and professional team is able to offer the right tools to distributors, OEM resellers and researchers with competitive product pricing. Moreover, providing the right information and useful suggestions to researchers are the core values of "TOOLS".

51 to 200 staff

Magqu Co., Ltd

MagQu focuses on creating new technologies and novel products. To do this, MagQu forms an interdisciplinary R&D team, as well as cooperates with professional institutes or experts in the areas of bio-chemistry, protein, nanomaterials, magnetism, electric engineering, software programming, laboratory medicine, clinic medicine, aquaculture etc. So far, MagQu has created more than six innovative technologies and has made them commercialized. Through the marketing of these novel products, we continuously increases its value, and keeps itself at the leading position in the relevant markets. We have utilized our core technology, so-called ImmunoMagnetic Reduction (IMR), to develop dozens of products, such as in-vitro diagnostic (IVD) assay kits and analyzers for colorectal cancer, Alzheimer’s disease, Down’s syndrome, preterm birth, inflammatory disease, grouper viruses etc. The R&D and manufacture of products have been certified with both ISO including 9001 and 13485, and GMP. We successfully made them on the shelf for life-science markets in China, Japan, Korea, Malaysia, Turkey, USA, UK, and Germany.

11 to 50 staff